Ashley Chan

Ashley Chan joined the OncLive team as an assistant editor in 2025 after previously working on the CURE editorial team since 2023.

Email: achan@mjhlifesciences.com

Articles

Ziftomenib Meets CR/CRh End Point in R/R NPM1+ AML

February 6th 2025

The oral menin inhibitor ziftomenib produced responses in patients with relapsed/refractory NPM1-mutant AML.

FDA Grants Orphan Drug Designation to 225Ac-Satoreotide for SCLC

February 6th 2025

The FDA has granted orphan drug designation to 225Ac-satoreotide for patients with small cell lung cancer.

Type II JAK Inhibitor AJ1-11095 Under Phase 1 Investigation in Myelofibrosis

February 5th 2025

AJ1-11095 is being evaluated in patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia.

Rovadicitinib Shows Safety, Clinical Activity After Ruxolitinib Intolerance in Myelofibrosis

February 5th 2025

The JAK/ROCK inhibitor rovadicitinib may provide a safe and effective new treatment option for patients with myelofibrosis who progressed on ruxolitinib.

Axi-Cel Shows Durable Responses, May Have Curative Potential in R/R Indolent Non-Hodgkin Lymphoma

February 4th 2025

Sattava S. Neelapu, MD, discusses updated data from the 5-year follow-up analysis evaluating axi-cel in relapsed/refractory indolent non-Hodgkin lymphoma.

Emavusertib Holds Potential for Combination Therapies in AML/MDS

February 4th 2025

Guillermo Garcia-Manero, MD, discusses the developmental progress of emavusertib for the treatment of acute myeloid leukemia and myelodysplastic syndromes.

Targeted Therapies for NSCLC With Nonclassical EGFR Mutations Grow Increasingly Personalized

February 4th 2025

The variety of nonclassical EGFR mutations in NSCLC necessitates the development of unique treatment strategies based on individual mutational profiles.

TAK-007 Shows Favorable Safety, Early Efficacy Data in R/R B-Cell Non-Hodgkin Lymphoma

February 4th 2025

A phase 2 study demonstrated that TAK-007 had a favorable safety profile with early efficacy in relapsed/refractory B-cell non-Hodgkin lymphoma.

Trend Towards Favorable DFS Observed With Cisplatin/Paclitaxel in HRD Advanced Ovarian Cancer

January 31st 2025

Cisplatin/paclitaxel showed trend towards improved DFS vs cisplatin alone in advanced-stage ovarian cancer.

Observational Data Challenge p53 Expression as a Surrogate Marker for TP53 Mutations in High-Risk Endometrial Cancer

January 30th 2025

An observational cohort study determined that discordance exists between p53 protein expression and TP53 mutation status in high-risk endometrial cancer.

European Commission Approves Blinatumomab Consolidation in Newly Diagnosed CD19+ B-ALL

January 30th 2025

The European Commission has approved blinatumomab as consolidation therapy for Ph-negative, CD19-postive B-cell precursor acute lymphoblastic leukemia.

CARGO Therapeutics to Discontinue Phase 2 Study of Firi-Cel in R/R LBCL

January 30th 2025

CARGO Therapeutics announced that it will discontinue the phase 2 FIRCE-1 trial evaluating firi-cel in relapsed/refractory large B-cell lymphoma.

Olaparib Elicits Improved OS Rates in Platinum-Sensitive, Germline/Somatic BRCA+ Relapsed Ovarian Cancer

January 29th 2025

A final analysis of the LIGHT trial showed olaparib demonstrated higher OS rates in patients with relapsed ovarian cancer who had germline or somatic BRCA mutations.

Routine Intraoperative Frozen Section Represents a "Very Costly" Soft Tissue Sarcoma Procedure

January 29th 2025

R. Lor Randall, MD, FACS, discusses the utility of routine intraoperative frozen section in soft tissue sarcomas and the impact of added costs.

Rapcabtagene Autoleucel May Be Safe and Efficacious in R/R DLBCL

January 28th 2025

Peter Riedell, MD, details the safety and efficacy of rapcabtagene autoleucel in relapsed/refractory diffuse large B-cell lymphoma.

NKT2152 Ushers in a New Era of HIF-2α Inhibition in Pretreated Advanced ccRCC

January 28th 2025

Toni Choueiri, MD, discusses the unique features of NKT2152, the agent’s safety profile in RCC, and future research directions across GU oncology.

Adagrasib/Cetuximab Maintains Efficacy in KRAS G12C–Mutated Advanced mCRC

January 27th 2025

A longer-term follow-up analysis showed that adagrasib/cetuximab demonstrated clinically meaningful efficacy in KRAS G12C–mutated advanced CRC.

2024 FDA Approvals Highlight New Treatment Considerations in HR+ Breast Cancer

January 22nd 2025

Eric Winer, MD, discusses the significance of 2 FDA approvals for HR-positive, HER2-negative breast cancer and emerging novel breast cancer treatments.

AVA6000 Elicits Clinically Meaningful Tumor Shrinkage in Salivary Gland Cancer

January 20th 2025

Preliminary data show that AVA6000 led to robust and clinically meaningful tumor shrinkage in patients with salivary gland cancer.

FDA Grants Orphan Drug Designation to ELC-100 for Pancreatic NETs

January 20th 2025

ELC-100 has been granted orphan drug designation by the FDA for the treatment of patients with pancreatic neuroendocrine tumors.